Related Experiment Video
Updated: Sep 28, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Phaeohyphomycotic infections in solid organ transplant patients
Julia B Garcia-Diaz1, Katherine Baumgarten
1Ochsner Clinic Foundation, Section of Infectious Diseases, Department of Medicine, Tulane University, New Orleans, LA 70121, USA. jgarcia-diaz@ochsner.org
Abstract:
Phaeohyphomycoses are darkly pigmented fungi that rarely cause infection in immunocompetent persons. In the past 2 decades these fungi increasingly have been reported as pathogens that cause significant morbidity and mortality in the immunocompromised host, especially solid organ transplant recipients. Clinical manifestations range from superficial lesions to disseminated infections. Exophiala spp. and Alternaria spp. account for the great majority of these infections. Treatment should include complete surgical excision of the lesions that are accessible combined with antifungal therapy, especially when invasive or systemic infection is present. Itraconazole usually suffices if only subcutaneous lesions are present; however, if the infection is systemic or it involves the central nervous system, the addition of amphotericin B is required. New investigational azoles also should be considered in these types of infections. This is a very heterogenous group of fungi and as such the sensitivities to antifungal agents is variable. Therefore, sensitivities should be obtained on every fungal isolate.
Insights
Phaeohyphomycoses, fungal infections from dark fungi, increasingly affect immunocompromised individuals, particularly transplant recipients. Treatment combines surgery with variable antifungal therapies, requiring sensitivity testing for effective management.
Area of Science:
- Mycology
- Infectious Diseases
- Immunocompromised Host Research
Background:
- Phaeohyphomycoses are infections caused by darkly pigmented fungi.
- These infections are rare in immunocompetent individuals but increasingly reported in immunocompromised hosts, especially solid organ transplant recipients.
- Clinical presentations vary from superficial to disseminated infections.
Purpose of the Study:
- To review the epidemiology, clinical manifestations, and treatment of phaeohyphomycoses.
- To highlight the challenges in managing these infections in immunocompromised patients.
Main Methods:
- Literature review of phaeohyphomycoses cases and treatment outcomes.
- Analysis of common causative agents like Exophiala spp. and Alternaria spp.
Main Results:
- Exophiala and Alternaria species are the predominant causes of phaeohyphomycoses.
- Treatment strategies depend on infection severity, ranging from surgical excision and itraconazole for subcutaneous lesions to amphotericin B for systemic or CNS involvement.
- Antifungal sensitivity testing is crucial due to variable fungal responses.
Conclusions:
- Phaeohyphomycoses pose a significant threat to immunocompromised individuals.
- A combination of surgical intervention and targeted antifungal therapy, guided by sensitivity testing, is essential for successful management.
- Emerging azole antifungals may offer alternative treatment options.
Related Concept Videos
Cryptococcal Meningitis
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Fungal Group Zygomycota
Fungal Phylum Microsporidia
Kidney Transplant II: Surgical Procedure
